000 01719 a2200433 4500
005 20250516223638.0
264 0 _c20150619
008 201506s 0 0 eng d
022 _a1098-2299
024 7 _a10.1002/ddr.21183
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMorado-Urbina, Carlos Eduardo
245 0 0 _aEarly, middle, or late administration of zoledronate alleviates spontaneous nociceptive behavior and restores functional outcomes in a mouse model of CFA-induced arthritis.
_h[electronic resource]
260 _bDrug development research
_cNov 2014
300 _a438-48 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAnimals
650 0 4 _aArthritis, Experimental
_xchemically induced
650 0 4 _aBone Density Conservation Agents
_xadministration & dosage
650 0 4 _aDiphosphonates
_xadministration & dosage
650 0 4 _aDose-Response Relationship, Drug
650 0 4 _aDrug Administration Schedule
650 0 4 _aEdema
_xcomplications
650 0 4 _aFreund's Adjuvant
650 0 4 _aImidazoles
_xadministration & dosage
650 0 4 _aMale
650 0 4 _aMice
650 0 4 _aMotor Activity
_xdrug effects
650 0 4 _aNociceptive Pain
_xcomplications
650 0 4 _aPain Measurement
_xdrug effects
650 0 4 _aZoledronic Acid
700 1 _aAlvarado-Vázquez, Perla Abigail
700 1 _aMontiel-Ruiz, Rosa Mariana
700 1 _aAcosta-González, Rosa Issel
700 1 _aCastañeda-Corral, Gabriela
700 1 _aJiménez-Andrade, Juan Miguel
773 0 _tDrug development research
_gvol. 75
_gno. 7
_gp. 438-48
856 4 0 _uhttps://doi.org/10.1002/ddr.21183
_zAvailable from publisher's website
999 _c24025415
_d24025415